Baseline demographics and disease characteristics (ITT population)
| Tocilizumab subcutaneous 162 mg/week (n=18) | Placebo (n=18) | |
| Female, n (%) | 16 (88.9) | 15 (83.3) |
| Age at informed consent, years, mean±SD (median) | 31.1±18.1 (26.5) | 30.8±13.1 (27.0) |
| Age category, n (%) | ||
| <18 years | 4 (22.2) | 2 (11.1) |
| 18–<65 years | 12 (66.7) | 15 (83.3) |
| ≥65 years | 2 (11.1) | 1 (5.6) |
| GC dose* at baseline, mg/kg, mean±SD (median) | 0.57±0.19 (0.50) | 0.52±0.16 (0.45) |
| GC dose* category, n (%) | ||
| <0.6 mg/kg | 13 (72.2) | 14 (77.8) |
| 0.6–<0.8 mg/kg | 2 (11.1) | 2 (11.1) |
| ≥0.8 mg/kg | 3 (16.7) | 2 (11.1) |
| Disease duration, years, mean±SD (median) | 6.46±7.37 (3.33) | 3.57±4.03 (2.89) |
| Classification of Takayasu arteritis, n (%) | ||
| I | 2 (11.1) | 2 (11.1) |
| IIA | 2 (11.1) | 3 (16.7) |
| IIB | 3 (16.7) | 5 (27.8) |
| III | 3 (16.7) | 1 (5.6) |
| IV | 0 | 0 |
| V | 8 (44.4) | 7 (38.9) |
| HLA-B52 positive, n (%) | 7 (38.9) | 13 (72.2) |
*Prednisolone equivalent (minimum dose was 0.4 mg/kg/day because patients who experienced relapse despite GC administration of at least 0.2 mg/kg/day were enrolled and received at least twice the dose they were receiving when relapse occurred).
GC, glucocorticoid; ITT, intent-to-treat.